Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

REGN Regeneron Pharmaceuticals

Closed 12-18 16:00:00 EST

748.71

-1.08

-0.14%

盘后746.90

-1.81-0.24%

19:53 EST

High752.84	Low739.23	Vol1.06M
Open747.54	D1 Closing749.79	Amplitude1.82%
Mkt Cap78.69B	Tradable Cap77.34B	Total Shares105.10M
T/O790.59M	T/O Rate1.02%	Tradable Shares103.30M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"Regeneron Pharmaceuticals","latestPrice":748.71,"timestamp":1766091600000,"preClose":749.79,"halted":0,"volume":1057594,"hourTrading":{"tag":"盘后","latestPrice":746.9,"preClose":748.71,"latestTime":"19:53 EST","volume":269345,"amount":201661106.46,"timestamp":1766105605096},"delay":0,"floatShares":103302739,"shares":105099464,"eps":41.59414,"marketStatus":"Closed","change":-1.08,"latestTime":"12-18 16:00:00 EST","open":747.54,"high":752.84,"low":739.23,"amount":790588319.2712001,"amplitude":0.018152,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":41.59414,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766134800000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":749.79,"dividendRate":0.004701,"preHourTrading":{"tag":"盘前","latestPrice":747,"preClose":749.79,"latestTime":"09:29 EST","volume":458,"amount":341990.8442,"timestamp":1766068199999},"postHourTrading":{"tag":"盘后","latestPrice":746.9,"preClose":748.71,"latestTime":"19:53 EST","volume":269345,"amount":201661106.46,"timestamp":1766105605096},"volumeRatio":1.2098,"impliedVol":0.3317,"impliedVolPercentile":0.168},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"2592974594","title":"Regeneron (REGN) Valuation Check After Lynozyfic Trial Success and New Gene Writing Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2592974594","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592974594?lang=en_us&edition=fundamental","pubTime":"2025-12-18 17:22","pubTimestamp":1766049762,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has caught investors attention after unveiling promising Phase 1/2 data for its multiple myeloma candidate Lynozyfic, along with fresh progress in gene writing and high profile scientific conference appearances.\nSee our latest analysis for Regeneron Pharmaceuticals.\nThose Lynozyfic results and the new gene writing collaboration have landed against a strong backdrop, with Regeneron’s 90 day share price return of 26.66 percent pointing to building momentum. The...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-regn-valuation-check-after-lynozyfic-trial-success","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/regeneron-regn-valuation-check-after-lynozyfic-trial-success","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0320765992.SGD","LU0109394709.USD","LU2023250504.SGD","LU1917777945.USD","LU0889565916.HKD","BK4588","LU2237438978.USD","LU0058720904.USD","BK4139","REGN","LU2362541273.HKD","LU1974910355.USD","LU0882574055.USD","LU0823434583.USD","LU0289739699.SGD","LU0114720955.EUR","LU0053666078.USD","LU2362540622.SGD","BK4585","LU2362541513.USD","LU2468319806.SGD","LU0823416689.USD","LU2089984988.USD","LU0823434740.USD","LU2106854487.HKD"],"gpt_icon":0},{"id":"2592918196","title":"Leerink Partners Adjusts Regeneron Pharmaceuticals PT to $873 From $710, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2592918196","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592918196?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:32","pubTimestamp":1765978333,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $802.17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic resea","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PT","REGN"],"gpt_icon":0},{"id":"2592992611","title":"Regeneron Pharmaceuticals Inc : Leerink Partners Raises Target Price to $873 From $710","url":"https://stock-news.laohu8.com/highlight/detail?id=2592992611","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592992611?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:09","pubTimestamp":1765973360,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XN0V8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0058720904.USD","LU0889565916.HKD","LU0882574055.USD","BK4139","LU2362541273.HKD","BK4588","LU0289739699.SGD","REGN","LU0823434740.USD","LU2468319806.SGD","LU1917777945.USD","LU1974910355.USD","LU2089984988.USD","LU0114720955.EUR","LU2362540622.SGD","LU0109394709.USD","LU2023250504.SGD","LU0053666078.USD","LU0823434583.USD","LU0320765992.SGD","LU0823416689.USD","LU2106854487.HKD","LU2362541513.USD","LU2237438978.USD","BK4585"],"gpt_icon":0},{"id":"2592016955","title":"GSK wins US approval for twice-yearly asthma drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2592016955","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592016955?lang=en_us&edition=fundamental","pubTime":"2025-12-17 08:01","pubTimestamp":1765929660,"startTime":"0","endTime":"0","summary":"UPDATE 2-GSK wins US approval for twice-yearly asthma drugAdds background throughout","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nL4N3XM1EK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU0306807586.USD","BK4581","LU1989771016.USD","LU1057294990.SGD","LU1571399168.USD","REGN","03165","AZN.UK","LU0345777659.USD","LU0225771236.USD","LU0052756011.USD","LU0738911758.USD","LU0114720955.EUR","GSK.UK","LU2133065610.SGD","LU0211326839.USD","LU1202635105.USD","LU1496350502.SGD","LU1670756490.USD","IE00BQJZX424.USD","LU0575583348.USD","LU2539964713.USD","LU1400636574.HKD","LU0171293334.USD","LU0289739699.SGD","LU2468319806.SGD","LU1880407215.USD","LU1267930573.SGD","LU0310800379.SGD","LU0320765992.SGD","LU0310800965.SGD","LU2324357040.USD","SG9999013999.USD","LU1261432733.SGD","LU0964806797.USD","BK5011","LU1267930227.SGD","LU1104425308.USD","LU1228905540.USD","LU1481599808.USD","AMGN","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU2362541513.USD","LU0128525929.USD","BK4585","LU0985481810.HKD","LU0784384876.USD","LU0792757196.USD"],"gpt_icon":0},{"id":"2590071815","title":"BRIEF-EMA's CHMP Recommended Granting Marketing Authorisation For Moderna's Mnexspike","url":"https://stock-news.laohu8.com/highlight/detail?id=2590071815","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590071815?lang=en_us&edition=fundamental","pubTime":"2025-12-12 23:11","pubTimestamp":1765552270,"startTime":"0","endTime":"0","summary":"BRIEF-EMA's CHMP Recommended Granting Marketing Authorisation For Moderna's MnexspikeDec 12  - EMA's CHMP:EMA'S CHMP: RECOMMENDED GRANTING MARKETING AUTHORISATION FOR MNEXSPIKE, FOR PREVENTION OF COVID-19 IN PEOPLE FROM 12 YEARS OF AGEEMA'S CHMP: RECOMMENDED CHANGE TO EXTEND USE OF MOUNJARO FOR TREATMENT OF A TYPE OF TYPE 2 DIABETESEMA'S CHMP: EXDENSUR  RECEIVED A POSITIVE OPINIONEMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR UPLIZNAEMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR NUCALAEMA'S CHMP: ADOPTED A POSITIVE OPINION FOR MYQORZO FOR TREATMENT OF ADULTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHYEMA'S CHMP: CONCLUDES REFERRAL FOR MELATOMED, RECOMMENDS MARKETING AUTHORISATION CAN BE GRANTEDEMA'S CHMP: RECOMMENDED EXTENSIONS OF INDICATION FOR AREXVY, ASPAVELI, DOVPRELA, ELUCIREM, EYLEA, NUCALA, RECARBRIO, SIMPONI, UPLIZNA, VUEWAYFurther company coverage: MRNA.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XI15S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1244550577.SGD","JNJ","LU0795875169.SGD","LU1989772923.USD","LU1868836591.USD","LU1814569148.SGD","SG9999014906.USD","LU1093756168.USD","LU2237443978.SGD","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU1035773651.USD","CYTK","LU1718418525.SGD","LU0323591593.USD","MRNA","SGXZ99366536.SGD","LU1127390331.HKD","LU0061475181.USD","BK4504","IE00BFTCPJ56.SGD","LU0385154629.USD","GSK.UK","LU1430594728.SGD","LU0640476718.USD","LU1934455194.USD","LU1974910355.USD","LU0256863902.USD","LU2242652126.USD","SGXZ57979304.SGD","REGN","LU0417517546.SGD","LU1699723380.USD","MRK","BK4139","LU1066053197.SGD","LU2360106947.USD","AMGN","LU1302929846.USD","IE0004445239.USD","SGXZ51526630.SGD","LU0912757837.SGD","IE00B1BXHZ80.USD","IE00B775H168.HKD","LU2236285917.USD","LU0079474960.USD","BK4505","LU0345769631.USD","LU1732799900.SGD"],"gpt_icon":1},{"id":"2590809502","title":"Morgan Stanley Adjusts Regeneron Pharmaceuticals PT to $768 From $767, Maintains Equalweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2590809502","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590809502?lang=en_us&edition=fundamental","pubTime":"2025-12-12 22:23","pubTimestamp":1765549431,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $795.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic resea","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REGN","PT"],"gpt_icon":0},{"id":"2590041825","title":"EMA Panel Recommends EU Approval of Bayer's Aflibercept 8 mg for Retinal Vein Occlusion","url":"https://stock-news.laohu8.com/highlight/detail?id=2590041825","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590041825?lang=en_us&edition=fundamental","pubTime":"2025-12-12 22:01","pubTimestamp":1765548076,"startTime":"0","endTime":"0","summary":"The Committee for Medicinal Products for Human Use  of the European Medicines Agency  has recommended Bayer AG's aflibercept 8 mg  for marketing authorization in the European Union for the treatment of visual impairment due to macular edema following retinal vein occlusion , including branch, central, and hemiretinal vein occlusion. This would be the third indication for Eylea 8 mg in the EU. Aflibercept 8 mg, known as Eylea HD in the United States, is being jointly developed by Bayer and Regeneron. The European Commission's final decision is expected in the coming weeks.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on December 12, 2025, and is solely responsibl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDLpHLHf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU0889565916.HKD","LU0882574055.USD","BK4139","LU2362541273.HKD","BK4588","LU0289739699.SGD","REGN","LU0823434740.USD","LU2468319806.SGD","LU1917777945.USD","LU1974910355.USD","LU2089984988.USD","LU0114720955.EUR","LU2362540622.SGD","LU0109394709.USD","LU2023250504.SGD","LU0053666078.USD","LU0823434583.USD","LU0320765992.SGD","LU0823416689.USD","LU2106854487.HKD","LU2362541513.USD","LU2237438978.USD","BK4585"],"gpt_icon":0},{"id":"2590728501","title":"Ema's Chmp: Recommended Extensions of Indication for Arexvy, Aspaveli, Dovprela, Elucirem, Eylea, Nucala, Recarbrio, Simponi, Uplizna, Vueway","url":"https://stock-news.laohu8.com/highlight/detail?id=2590728501","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590728501?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:35","pubTimestamp":1765546550,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XI15S:8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1074936037.SGD","LU1935042991.SGD","LU1481599808.USD","IE00B19Z3581.USD","LU0320765489.SGD","LU0203347892.USD","BK4588","LU0823416689.USD","LU1244550577.SGD","LU0795875169.SGD","LU2125154935.USD","GSK.UK","JNJ","BK4550","LU0225771236.USD","LU1267930813.SGD","BK4516","LU1917777945.USD","LU0345770308.USD","LU0289739699.SGD","IE00BVYPNV92.GBP","LU2361044949.HKD","REGN","LU1196500208.SGD","IE00B3T34201.USD","LU1400636574.HKD","LU1894683264.USD","SG9999015358.SGD","LU2324357040.USD","LU1291159041.SGD","LU1674673691.USD","LU0109394709.USD","LU0130517989.USD","LU2430703178.SGD","LU1261432733.SGD","LU2362541513.USD","LU1069347547.HKD","LU2471134796.USD","LU2361044865.SGD","MRK","LU1015430645.USD","LU0861579265.USD","IE00BKVL7J92.USD","LU0320765992.SGD","LU2750360997.AUD","LU0234572021.USD","LU1934455277.USD","LU0265550359.USD","LU1309081286.SGD","LU1506573853.SGD"],"gpt_icon":0},{"id":"2590508533","title":"Exclusive-U.S. FDA Presses for Reviewers to Speed up Evaluation of Eli Lilly's Weight-Loss Pill -Internal Documents","url":"https://stock-news.laohu8.com/highlight/detail?id=2590508533","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590508533?lang=en_us&edition=fundamental","pubTime":"2025-12-12 19:00","pubTimestamp":1765537200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"88e4ec322662429deaabe33a5ac0ce39","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nL6N3XH00W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0466842654.USD","LU2087625088.SGD","LU2168563687.JPY","LU0006306889.USD","LU0943347566.SGD","LU2361045086.USD","LU2491050071.SGD","SG9999015945.SGD","LU2063271972.USD","LU0823434740.USD","LU2456880835.USD","LU0198837287.USD","LU0234572021.USD","LLY","LU0432979614.USD","LU2108987350.USD","LU1323610961.USD","LU1057294990.SGD","LU1868836591.USD","LU0471298694.HKD","IE00BK4W5L77.USD","LU2237443978.SGD","SG9999014914.USD","LU2552382058.USD","BK4588","SG9999018857.SGD","LU0882574055.USD","LU0203201768.USD","LU0672654240.SGD","LU1093756325.SGD","LU2237443465.HKD","IE0002141913.USD","LU0289739699.SGD","LU2552382132.HKD","LU1868836914.USD","LU2362541273.HKD","SG9999015986.USD","REGN","LU0079474960.USD","IE00BK4W5M84.HKD","LU0266013472.USD","LU2362541513.USD","LU0256863902.USD","LU2237443549.SGD","LU0820561818.USD","LU0096364046.USD","LU1868837136.USD","SG9999015952.SGD","BK4516","LU0823416689.USD"],"gpt_icon":0},{"id":"2590083075","title":"Exclusive-FDA Could Issue Decision on Lilly's Pill as Early as March 28 IF New Timeline Adopted","url":"https://stock-news.laohu8.com/highlight/detail?id=2590083075","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590083075?lang=en_us&edition=fundamental","pubTime":"2025-12-12 19:00","pubTimestamp":1765537200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"88e4ec322662429deaabe33a5ac0ce39","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nL6N3XH00W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LLY","LU2168563687.JPY","LU0432979614.USD","LU2089984988.USD","LU0353189763.USD","LU2168564065.EUR","LU2750360997.AUD","REGN","SG9999018857.SGD","LU0823416689.USD","GB00BDT5M118.USD","LU0266013472.USD","LU1232071149.USD","BK4581","IE00B775H168.HKD","LU2168564495.EUR","LU2471134523.USD","LU1720051108.HKD","LU1093756325.SGD","LU0256863811.USD","LU2456880835.USD","LU2362540622.SGD","LU1127390331.HKD","LU1064131342.USD","IE00B2B36J28.USD","LU1868837300.USD","LU1804176565.USD","IE00B7KXQ091.USD","LU1093756168.USD","LU2491050154.USD","LU0471298694.HKD","LU0006306889.USD","LU1280957306.USD","LU2023250504.SGD","LU0320765059.SGD","LU2462157665.USD","LU0256863902.USD","LU1291159041.SGD","LU2746668974.SGD","LU2237438978.USD","LU1917777945.USD","LU1551013342.USD","SG9999015952.SGD","LU0203201768.USD","SGXZ31699556.SGD","LU0466842654.USD","LU1974910355.USD","LU0354030511.USD","BK4007","BK4139"],"gpt_icon":0},{"id":"2590541031","title":"Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2590541031","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590541031?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:43","pubTimestamp":1765489380,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  rose 2.84% to $746.80 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index  rising 0.21% to 6,901.00 and the Dow Jones Industrial Average  rising 1.34% to 48,704.01.This was the stock's second consecutive day of gains.Regeneron Pharmaceuticals Inc. closed 5.59% short of its 52-week high of $790.98, which the company reached on November 26th.The stock outperformed some of its competitors Thursday, as Amgen Inc.  rose 0.63% to $317.38, Moderna Inc.  rose 2.07% to $29.63, and Gilead Sciences Inc.  rose 1.54% to $123.21.Trading volume  eclipsed its 50-day average volume of 1.1 M.Data source: Dow Jones Market Data, FactSet. Data compiled December 11, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswir","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"2590102445","title":"BUZZ-Biohaven jumps as cancer treatment shows promise in early-stage trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590102445","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590102445?lang=en_us&edition=fundamental","pubTime":"2025-12-12 00:31","pubTimestamp":1765470697,"startTime":"0","endTime":"0","summary":"BUZZ-Biohaven jumps as cancer treatment shows promise in early-stage trial** Shares of drugmaker Biohaven BHVN.N rise 8.5% to $11.50 ** Co says its experimental therapy, BHV-1510, in combination with Regeneron Pharmaceuticals' REGN.O Libtayo, showed efficacy and manageable safety across several tumors in an early-stage trial** Co says patients receiving the treatment every three weeks showed a 72.7% confirmed response** The combination therapy is being tested among pre-treated patients with advanced cancers - BHVN** RBC Capital Markets says it \"sees these efficacy and safety results as promising\"** Including session moves, stock down 69.2% YTD   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nL4N3XH18A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","BK4585","LU0823416689.USD","LU1093756168.USD","LU0114720955.EUR","LU0109394709.USD","LU2362541273.HKD","LU0882574055.USD","LU1093756325.SGD","BK4588","LU2362541513.USD","LU0053666078.USD","LU0823434740.USD","LU1974910355.USD","LU2106854487.HKD","LU2237438978.USD","LU2468319806.SGD","LU1917777945.USD","REGN","LU2023250504.SGD","BHVN","LU0320765992.SGD","BK4139","LU2362540622.SGD","LU0289739699.SGD","LU0823434583.USD","LU0889565916.HKD","LU2089984988.USD"],"gpt_icon":0},{"id":"2590103315","title":"BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EST on 2025-12-11","url":"https://stock-news.laohu8.com/highlight/detail?id=2590103315","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590103315?lang=en_us&edition=fundamental","pubTime":"2025-12-12 00:01","pubTimestamp":1765468879,"startTime":"0","endTime":"0","summary":"BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EST on 2025-12-11Nasdaq 100 .NDXTop PerformersPercent ChangeMercadoLibre Inc MELI.OQ+2.7%Regeneron Pharmaceuticals Inc REGN.OQ+2.4%Old Dominion Freight Line Inc ODFL.OQ+2.2%Marriott International Inc MAR.OQ+2.2%Applovin Corp APP.OQ+2.1%Bottom PerformersPercent ChangeStrategy Inc MSTR.OQ-6.3%Trade Desk Inc TTD.OQ-5.3%Arm Holdings PLC ARM.OQ-4.7%Marvell Technology Inc MRVL.OQ-4.4%Advanced Micro Devices Inc AMD.OQ-3.7%The Nasdaq 100 .NDX lost 269.31 points, or 1.04%, to 25,507.12 and recorded one new high and 2 new lows. 54 stocks rose and 47 fell as advancing issues outnumbered decliners by a about a 1.1-to-1 ratio.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nL8N3XH1JJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSTR","IE00BGV7N243.SGD","LU0210535034.USD","LU0456842615.SGD","LU0690374615.EUR","LU1803068979.SGD","LU1119994496.HKD","IE00B95QR487.USD","IE00BLSP4452.SGD","LU0719512351.SGD","BK4534","LU1720051017.SGD","LU2360106780.USD","BK4612","LU1988902786.USD","BK4139","LU0274383776.USD","LU0289960550.SGD","LU2087625088.SGD","IE00BBT3K403.USD","LU0353189763.USD","LU0109392836.USD","IE00BMPRXQ63.HKD","IE0009356076.USD","IE00B894F039.SGD","BK4614","BK4515","LU0354030511.USD","LU2279701549.SGD","LU2089985449.USD","LU1261432733.SGD","MAR","SG9999000418.SGD","BK4532","LU0431992006.USD","IE00B19Z9Z06.USD","MELI","SGXZ99366536.SGD","BK4539","LU2357305700.SGD","LU1046421795.USD","REGN","BK4141","GB00B4QBRK32.GBP","LU1804176565.USD","LU1861558580.USD","LU0532187761.SGD","LU2244417387.USD","LU1861559042.SGD","BK4232","BK4554","GB00BDT5M118.USD","LU1861220033.SGD","LU2063271972.USD","LU2250418816.HKD","LU0354030438.USD","LU1169590202.USD","LU2211815571.USD","LU2404859667.USD","LU0289961442.SGD","LU0868486357.SGD","LU0289739699.SGD","IE00B5949003.HKD","LU0057025933.USD","LU0476273544.USD","LU1992135399.USD","LU1923623000.USD","LU1084165304.USD","LU1242518931.SGD","LU0109394709.USD","BK4142","LU1951200564.SGD","LU2931357623.SGD","STRK","LU0053666078.USD","BK4588","LU1861215975.USD","LU1917777945.USD","LU1235294995.USD","LU0143863198.USD","LU2355687059.USD","IE00B8HQ1Z84.USD","LU2265009873.SGD","LU0786609619.USD","SGXZ81514606.USD","APP","IE00B19Z9P08.USD","LU0957808578.USD","IE00B1B80R65.USD","LU0058720904.USD","LU0143863784.USD","BK4605","LU2023250504.SGD","IE00B45NX917.SGD","LU0069063385.USD","LU1868838027.USD","LU2264538146.SGD","LU2237438978.USD","LU2360107168.USD","BK4543","IE00B0JY6N72.USD","LU1303367103.USD","BK4566","LU2458330243.SGD","SGXZ51526630.SGD","LU1548497426.USD","LU2322448791.USD","LU2089984988.USD","LU2468319806.SGD","IE00BMPRXR70.SGD","BK4604","BK4528","BK4600","LU1718418525.SGD","LU1316542783.SGD","LU2362540622.SGD","LU0175139822.USD","BK4613","LU0690374961.EUR","LU2097829019.USD","BK4609","LU0889565916.HKD","BK4548","LU0082616367.USD","LU2290526834.HKD","ODFL","LU0823421333.USD","BK4022","LU1815336760.USD","LU0097036916.USD","LU0106959298.USD","LU0107464264.USD","LU0511384066.AUD","LU0050427557.USD","LU0823411888.USD","LU0154236417.USD","IE00BD0PCF45.HKD","LU1880398554.USD","LU1989764664.SGD","IE00BLSP4239.USD","LU1169589451.USD","BK4220","LU0353189680.USD","LU2458330169.SGD","LU0823421416.USD","BK4581","LU0642271901.SGD","LU1992135472.HKD","LU0061475181.USD","LU2054465674.USD","LU0187121727.USD","BK4595","BK4023","LU0979878070.USD","BK4516","BK4533","GB00B4LPDJ14.GBP","LU2362541273.HKD","IE00BN8TJ469.HKD","BK4529","IE0004445239.USD","LU1974910355.USD","LU2473716301.USD","LU1880398471.USD","IE00BMPRXN33.USD","LU1868837565.USD","LU2106854487.HKD","LU0053687314.USD","LU0114720955.EUR","LU2272731865.HKD","IE0008368304.USD","LU1852331112.SGD","LU0823416689.USD","LU0289739343.SGD","LU0444973449.USD","BK4585","LU2404859741.USD","BK4122","BK4504","IE00B8L5B284.USD","LU0056508442.USD","IE00B0169N27.USD","LU0348723411.USD","LU0444971666.USD","LU0823434740.USD","LU1064131342.USD","TTD","LU0198837287.USD","BK4512","IE00BZ9MQY76.HKD","LU1823568750.SGD","BK4575","LU0390134368.USD","LU1951198990.SGD","LU0081259029.USD","LU0127658192.USD","BK4009","LU0823434583.USD","LU2272731782.SGD","IE00B1G9WX41.USD","LU2322448957.HKD","LU2362541513.USD","MRVL","LU2543165471.USD","LU1868837722.USD","IE00B0T0GQ85.USD","LU1242518857.USD","LU1720051108.HKD","LU2272731600.USD","LU0320765992.SGD","LU1642822529.SGD","BK4608","BK4573","LU0889565833.HKD","BK4596","LU0472753341.HKD","LU0882574055.USD","ARM","AMD","LU2098885051.SGD","LU1989764748.USD"],"gpt_icon":1},{"id":"2590454553","title":"Regeneron Pharmaceuticals Inc. Stock Rises 4.9%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2590454553","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590454553?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:35","pubTimestamp":1765402500,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc. rose 4.9% to $726.21 on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.7% to 6,886.68 and the Dow Jones Industrial Average rising 1.0% to 48,057.75.The stock's rise snapped a nine-day losing streak.Regeneron Pharmaceuticals Inc. closed 8.2% short of its 52-week high of $790.98, which the company reached on November 26th.The stock outperformed some of its peers, as Amgen Inc. rose 0.5% to $315.38, Moderna Inc. rose 2.8% to $29.03, and Gilead Sciences Inc. rose 1.66% to $121.34.Trading volume totaled 1.3 million, compared to the 50-day average of 1.1 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"2590355584","title":"Wells Fargo Adjusts PT on Regeneron Pharmaceuticals to $745 From $700, Maintains Equalweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2590355584","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590355584?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:10","pubTimestamp":1765368654,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $795.13, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic resea","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REGN","PT"],"gpt_icon":0},{"id":"2590329763","title":"Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590329763","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590329763?lang=en_us&edition=fundamental","pubTime":"2025-12-10 04:33","pubTimestamp":1765312385,"startTime":"0","endTime":"0","summary":"Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial Health Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us?Forward this newsletter to them. They can also subscribe hereBy Nancy LapidDec 9  - Hello Health Rounds readers!","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nL1N3XA139:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417517546.SGD","LU2237443382.USD","IE00BJJMRX11.SGD","LU2237443622.USD","LU0471298777.SGD","LU1496350171.SGD","LU0823416689.USD","LU2112291526.USD","IE0005OL40V9.USD","LU0114720955.EUR","LU2089984988.USD","LU0784383803.USD","SG9999001176.USD","LU0471298694.HKD","LU1989771016.USD","LU1868836914.USD","LU2471134523.USD","LU0052756011.USD","LU0122379950.USD","LU0553294199.USD","SG9999018857.SGD","LU0094547139.USD","LU0171293334.USD","LU0053666078.USD","LU1267930227.SGD","LU1917777945.USD","SG9999014880.SGD","LU0557290698.USD","LU1496350502.SGD","SG9999017495.SGD","SGXZ99366536.SGD","LU2456880835.USD","LU2265009873.SGD","LU2237443549.SGD","LU1720051017.SGD","BK4534","LU0256863902.USD","LU0964806797.USD","GB00BDT5M118.USD","SG9999001176.SGD","LU1487256676.USD","IE00BJLML261.HKD","LU0109394709.USD","LU1804176565.USD","IE00B2B36J28.USD","LU2468319806.SGD","LU0889565916.HKD","LU2362540622.SGD","LU0109391861.USD","LU1261432733.SGD","SGXZ31699556.SGD","LU2362541513.USD","LU0211327993.USD","LU0786609619.USD","LU1323610961.USD","LU2491049909.HKD","LU0738911758.USD","LU0345777147.USD","LU0957799991.USD","LU0972486137.USD","LU1019632923.USD","LU1093756325.SGD","LU1868836757.USD","LU2023251221.USD","LU2750360997.AUD","LU2108987350.USD","LU2539964713.USD","LU2237443895.HKD","LU1051770623.HKD","LU0256863811.USD","LU0211328371.USD","LU0661504455.SGD","LU0882574139.USD","LU0969580561.USD","LU2746668461.USD","SG9999013999.USD","LU0079474960.USD","LU0784384876.USD","LU2168564149.EUR","LU1232071149.USD","IE0002141913.USD","LU0784385170.HKD","LU0310799852.SGD","SG9999015952.SGD","SGXZ57979304.SGD","BK4533","LU2491050071.SGD","LU2168564495.EUR","IE00BKPKM643.USD","LU0640476718.USD","LU1003076772.USD","IE00B4JS1V06.HKD","BK4516","IE00BJJMRY28.SGD","LU0097036916.USD","LU2114397693.USD","LU0158827948.USD","SGXZ81514606.USD","LU1061106388.HKD","LU0203201768.USD","LU0689472784.USD","LU1064131342.USD","IE00B1BXHZ80.USD","LU0096364046.USD","LU1093756168.USD","BK4599","LU0823399737.USD","LU1623119135.USD","LU1814569148.SGD","LU1551013425.SGD","LU0545039389.USD","LU2087625088.SGD","LU2552382058.USD","LU2168564065.EUR","LU1267930573.SGD","LU0011850046.USD","LU2091194634.USD","LU1153585028.USD","LU1868837136.USD","LU1104425308.USD","LU0058720904.USD","LU0353189680.USD","LU0943347566.SGD","LU1267930490.SGD","LU2471134796.USD","SG9999018865.SGD","LU0354030511.USD","LU0047473722.SGD","LU1015430645.USD","IE00BK4W5L77.USD","LU2237438978.USD","LU2362541273.HKD","LU0345777659.USD","LU0203202063.USD","LU1019634622.SGD","LU0385154629.USD","LU2089284900.SGD","LU1548497426.USD","LU0320765992.SGD","IE00BJJMRZ35.SGD","LU2471134952.CNY","LU2552382132.HKD","BK4585","LU1084165304.USD","LU0077335932.USD","LU0784385840.USD","LU0960981461.USD","LU1868836591.USD","LU0963555726.SGD","LU1481600234.SGD","LU0353189763.USD","IE00B1XK9C88.USD","LU2023250504.SGD","LU0106261372.USD","LU0976567544.SGD","LU0466842654.USD","LU1267930730.SGD","LU2471134879.HKD","LU2168563687.JPY","LU0526926950.USD","LU1280957306.USD","IE00BKDWB100.SGD","LU1366192091.USD","LU0316494557.USD","IE00B4R5TH58.HKD","LU0640478417.SGD","LU1078025761.USD","LU2746668974.SGD","SG9999014914.USD","IE0034235188.USD","LU1880407132.USD","LU1267930813.SGD","LU0061475181.USD","LU0289739699.SGD","LU0499090636.EUR","LU1069344957.HKD","LU1868837300.USD","LU2211815571.USD","REGN","SG9999015945.SGD","LU1880407215.USD","LU0757432116.USD","LU2293690082.USD","LU0456855351.SGD","LU2293690249.USD","LU2324357040.USD","LU0310800965.SGD","LU0949170772.SGD","LU1023059063.AUD","IE00BFSS8Q28.SGD","LU0238689110.USD","LU2491050154.USD","LU0128525689.USD","LU2236285917.USD","LU0211326755.USD","IE00BFTCPJ56.SGD","LU2237443465.HKD","SG9999014898.SGD","IE0004445015.USD","BK4007","LU2357305700.SGD","IE0009355771.USD","LU1035775433.USD","BK5011","03165","SG9999015986.USD","LU2264538146.SGD","LU0234572021.USD","LU2360106947.USD","LU0820561909.HKD","LU2237443978.SGD","LU0323591593.USD","LU0198837287.USD","LU1988902786.USD","LU1057294990.SGD","LU0006306889.USD","LU0496365809.HKD","LU0203345920.USD","IE00B7KXQ091.USD","LU2361045086.USD","LU0820561818.USD","LU1481599808.USD","SGXZ51526630.SGD","LU1119994496.HKD","LU2462157665.USD","LU0203347892.USD","BK4588","IE00BK4W5M84.HKD","LU1003077747.HKD","LU1989772923.USD","LU0029864427.USD","LU1551013342.USD","BK4139","BK4581","IE00BN29S564.USD","LU0792757196.USD","LU0882574055.USD","LU1301847155.USD","IE00BFSS7M15.SGD","LU1127390331.HKD","LU0310800379.SGD","LU0889565080.SGD","LU0432979614.USD","LU1064927863.SGD","LU1720051108.HKD","LU2089283258.USD","LU2361044949.HKD","LU2133065610.SGD","LU2168564222.USD","LU0211326839.USD","LU0672654240.SGD","LU2417539215.USD","SG9999014906.USD","IE00B3T34201.USD","LU1712237335.SGD","LU1153584641.USD","IE0004445239.USD","LU2461242641.AUD","IE00BJT1NW94.SGD","LU1291159041.SGD","LU2063271972.USD","LU2106854487.HKD","IE00BKPKM429.USD","LU0823434740.USD","LU0889566641.SGD","LU1974910355.USD","LU0266013472.USD","SG9999015978.USD","LU0047473722.EUR","LU2361044865.SGD","IE00BWXC8680.SGD","LU0949170426.SGD","LU2750360641.GBP","LU0575583348.USD","LU1983299246.USD","LU1989772840.SGD","LU2552382215.SGD","LU0997586432.USD","LU0708995401.HKD","IE00B775H168.HKD","LU2602419157.SGD","LU0320765059.SGD","LU0823434583.USD","LU0354030438.USD","LU0708994859.HKD","LU2279689827.SGD","LU0128525929.USD"],"gpt_icon":0},{"id":"2590332818","title":"Regeneron Pharmaceuticals' Upcoming Melanoma Data Likely to Look Competitive, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2590332818","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590332818?lang=en_us&edition=fundamental","pubTime":"2025-12-10 00:28","pubTimestamp":1765297720,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals'  upcoming LAG-3 melanoma readout will likely look competitive, RBC Capital Markets said in a note Tuesday.The investment firm said Regeneron market expectations for Regeneron's \"peak sales numbers do have room to move up.\"However, based on RBC's analysis and other feedback, it is not certain that the differentiation versusBristol-Myers Squibb's  Opdualag will be \"indisputable enough to drive another major leg of major stock upside from here,\" the note said.The investment firm said the first phase 3 results from the LAG-3 fianlimab plus cemiplimab combo versus pembro to treat 1L metastatic melanoma are expected in H1 2026.RBC has a sector perform rating on Regeneron and $708 price target.Price: 699.73, Change: -3.53, Percent Change: -0.50","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0823416689.USD","LU0237698245.USD","LU1670711040.USD","LU0289739699.SGD","LU1074936037.SGD","LU1323610961.USD","LU1868836914.USD","LU0321505439.SGD","LU1093756325.SGD","IE0009355771.USD","LU0985481810.HKD","LU0109394709.USD","BK4534","LU0823434740.USD","LU0053666078.USD","LU1917777945.USD","BK4139","LU1093756168.USD","LU2242652126.USD","LU1868837136.USD","IE00BJT1NW94.SGD","LU0061475181.USD","IE00B2B36J28.USD","BK4559","BK4532","LU2237438978.USD","BK4007","LU0306806265.USD","LU0096364046.USD","IE0002141913.USD","LU1868836591.USD","REGN","LU1670710588.SGD","LU2362541273.HKD","LU0456855351.SGD","LU2089984988.USD","LU1430594728.SGD","LU1974910355.USD","LU0225284248.USD","LU2125154935.USD","LU2242646821.SGD","LU1670710661.SGD","LU2106854487.HKD","LU0306807586.USD","BMY","LU2362540622.SGD","LU2468319806.SGD","LU1670711123.USD","LU1868836757.USD","LU1291159041.SGD"],"gpt_icon":0},{"id":"2590366491","title":"Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2590366491","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590366491?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:42","pubTimestamp":1765230120,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  slid 2.10% to $703.26 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index  falling 0.35% to 6,846.51 and Dow Jones Industrial Average  falling 0.45% to 47,739.32.This was the stock's eighth consecutive day of losses.Regeneron Pharmaceuticals Inc. closed 12.20% below its 52-week high of $800.99, which the company reached on December 9th.The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Amgen Inc.  fell 2.63% to $321.23, Moderna Inc.  rose 0.97% to $27.97, and Gilead Sciences Inc.  fell 0.02% to $121.19.Trading volume  remained 165,791 below its 50-day average volume of 1.1 M.Data source: Dow Jones Market Data, FactSet. Data compiled December 8, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is publishe","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"2590357184","title":"Regeneron Pharmaceuticals Currently Down Eight Consecutive Days, on Track for Longest Losing Streak Since May 2018 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2590357184","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590357184?lang=en_us&edition=fundamental","pubTime":"2025-12-09 01:11","pubTimestamp":1765213860,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals, Inc.  is currently at $710.00, down $8.36 or 1.16%. --Would be lowest close since Nov. 19, 2025, when it closed at $702.75. --On pace for largest percent decrease since Dec. 3, 2025, when it fell 2.47%. --Currently down eight consecutive days; down 9.82% over this period. --Longest losing streak since May 9, 2018, when it fell for nine straight trading days. --Down 9.90% from 52 weeks ago , when it closed at $788.00. --Up 46.98% from its 52-week closing low of $483.07 on June 5, 2025. --Traded as low as $704.29; lowest intraday level since Nov. 19, 2025, when it hit $702.63","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU2362541273.HKD","LU0109394709.USD","LU0882574055.USD","LU0823416689.USD","LU2468319806.SGD","LU0889565916.HKD","BK4139","LU0053666078.USD","LU1974910355.USD","LU0320765992.SGD","LU0289739699.SGD","LU2023250504.SGD","LU2089984988.USD","REGN","LU0823434583.USD","LU2362540622.SGD","LU2237438978.USD","LU2362541513.USD","LU0114720955.EUR","BK4585","LU0823434740.USD","LU2106854487.HKD","BK4588","LU1917777945.USD"],"gpt_icon":0},{"id":"2589302933","title":"BUZZ-Ocular Therapeutix rises on plans to fast-track FDA filing for eye disease drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2589302933","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589302933?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:26","pubTimestamp":1765196774,"startTime":"0","endTime":"0","summary":"BUZZ-Ocular Therapeutix rises on plans to fast-track FDA filing for eye disease drug** Shares of Ocular Therapeutix OCUL.O rise 13.5% to $14.28 in premarket trading** OCUL says its plans to submit a marketing application for its experimental eye disease drug, Axpaxli, to treat wet age-related macular degeneration after one-year data from its ongoing late-stage trial, expected in the first quarter of 2026** Wet AMD is a leading cause of vision loss in older adults, marked by abnormal blood vessel growth in the retina     ** Company says the study is designed to show superiority over Regeneron Pharma's REGN.O Eylea and aligns with recent FDA guidance that a single, well-controlled trial may support approval** As of last close, stock up 47.3% YTD   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL4N3XE0UN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU2362541273.HKD","LU0109394709.USD","LU0882574055.USD","LU0823416689.USD","LU2468319806.SGD","LU0889565916.HKD","BK4139","LU0053666078.USD","LU1974910355.USD","LU0320765992.SGD","LU0289739699.SGD","LU2023250504.SGD","LU2089984988.USD","REGN","LU0823434583.USD","LU2362540622.SGD","LU2237438978.USD","BK4007","LU2362541513.USD","LU0114720955.EUR","OCUL","BK4585","LU0823434740.USD","LU2106854487.HKD","BK4588","LU1917777945.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":0.0325},{"period":"1month","weight":0.0646},{"period":"3month","weight":0.2523},{"period":"6month","weight":0.471},{"period":"1year","weight":0.0132},{"period":"ytd","weight":0.0526}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.529412,"avgChangeRate":0.03899},{"month":2,"riseRate":0.411765,"avgChangeRate":0.087815},{"month":3,"riseRate":0.470588,"avgChangeRate":-0.044318},{"month":4,"riseRate":0.470588,"avgChangeRate":0.017191},{"month":5,"riseRate":0.628571,"avgChangeRate":0.057479},{"month":6,"riseRate":0.428571,"avgChangeRate":0.006745},{"month":7,"riseRate":0.657143,"avgChangeRate":0.052646},{"month":8,"riseRate":0.542857,"avgChangeRate":0.022877},{"month":9,"riseRate":0.457143,"avgChangeRate":0.023281},{"month":10,"riseRate":0.4,"avgChangeRate":-0.00141},{"month":11,"riseRate":0.542857,"avgChangeRate":0.046018},{"month":12,"riseRate":0.485714,"avgChangeRate":0.042995}],"exchange":"NASDAQ","name":"Regeneron Pharmaceuticals","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Regeneron Pharmaceuticals,REGN,Regeneron Pharmaceuticals股票,Regeneron Pharmaceuticals股票老虎,Regeneron Pharmaceuticals股票老虎国际,Regeneron Pharmaceuticals行情,Regeneron Pharmaceuticals股票行情,Regeneron Pharmaceuticals股价,Regeneron Pharmaceuticals股市,Regeneron Pharmaceuticals股票价格,Regeneron Pharmaceuticals股票交易,Regeneron Pharmaceuticals股票购买,Regeneron Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction